Einat Zisman
Directeur/Membre du Conseil chez Plantylight Ltd.
Profil
Einat Zisman is currently a Director at Plantylight Ltd.
She previously served as President & CEO at Hadasit Medical Research Services & Development Ltd.
and as CEO & Director at FutuRx Ltd.
She also held director positions at HBL- Hadasit Bio-Holdings Ltd., SciSparc Ltd., ProtAb Ltd., Enlivex Therapeutics Ltd., KAHR Medical Ltd., Bio-MarCare Technologies Ltd., and was Chief Business Officer at Yeda Research & Development Co. Ltd.
Zisman holds an MBA from the University of Southern California, an undergraduate degree from The Hebrew University of Jerusalem, a graduate degree from Ben-Gurion University of the Negev, and a doctorate from the Weizmann Institute of Science.
Postes actifs de Einat Zisman
| Sociétés | Poste | Début |
|---|---|---|
| Plantylight Ltd. | Directeur/Membre du Conseil | - |
Anciens postes connus de Einat Zisman
| Sociétés | Poste | Fin |
|---|---|---|
FutuRx Ltd.
 FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | Directeur Général | 01/01/2018 |
ProtAb Ltd.
 ProtAb Ltd. Pharmaceuticals: MajorHealth Technology ProtAb Ltd. develops drug treatment for rheumatoid arthritis. It develops therapeutic agents that modulate cytokine regulation, tipping the balance toward anti-inflammatory signaling pathways in the treatment of autoimmune inflammatory diseases. The company was Founded by Yaakov Naparstek in 2005 and is headquartered in Jerusalem, Israel. | Directeur/Membre du Conseil | - |
| HBL - HADASIT BIO-HOLDINGS LTD | Directeur/Membre du Conseil | - |
Enlivex Therapeutics Ltd. /Old/
 Enlivex Therapeutics Ltd. /Old/ Medical SpecialtiesHealth Technology Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn’s disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company was founded by Dror Mevorach in 2005 and is headquartered in Jerusalem, Israel. | Directeur/Membre du Conseil | - |
Yeda Research & Development Co. Ltd.
 Yeda Research & Development Co. Ltd. Investment ManagersFinance Yeda Research & Development Co. Ltd. engages in development of natural science and services. It covers broad of spectrum including: biotechnology, pharmaceuticals and diagnostics, bioinformatics, proteomics, biomatics and system biology, medical devices, renewable energy, bio fuels, clean technology and environmental sciences, agricultural and plants genetics, chemistry and nanotechnology, physics and electro-optics, mathematics and computer science. The company is headquartered in Rehovot, Israel. | Corporate Officer/Principal | - |
Formation de Einat Zisman
| Weizmann Institute of Science | Doctorate Degree |
| The Hebrew University of Jerusalem | Undergraduate Degree |
| University of Southern California | Masters Business Admin |
| Ben-Gurion University of the Negev | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SCISPARC LTD. | Health Technology |
| HBL - HADASIT BIO-HOLDINGS LTD | Finance |
| Entreprise privées | 8 |
|---|---|
Hadasit Medical Research Services & Development Ltd.
 Hadasit Medical Research Services & Development Ltd. Miscellaneous Commercial ServicesCommercial Services Hadasit Medical Research Services & Development Ltd. operates as technology transfer company of Hadassah Medical Center in Jerusalem. It identifies, protects, nurtures and commercializes the discoveries made at Hadassah Medical Center. The company's product include Doxil, Periochip, Travelan, Granagard, and Insupad. The company was founded on December 7, 1986 and is headquartered in Jerusalem, Israel. | Commercial Services |
KAHR Medical Ltd.
 KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | Health Technology |
Bio-MarCare Technologies Ltd.
 Bio-MarCare Technologies Ltd. Medical/Nursing ServicesHealth Services Bio-MarCare Technologies Ltd. develops diagnostic kits based on novel biomarkers for early cancer identification, monitoring and assistance. Its product mCRC-Strat is a personalized medicine assay predicting responsiveness to anti EGFR therapy and Colon-MarCarePlex is a molecular assay (qRT-PCR) comprising a panel of RNA markers that can detect the advanced adenoma polyps as well as early stage colorectal cancer. The company was founded by Beatrice Uziely and Rachel Bar-Shavit in 2002 and is headquartered in Jerusalem, Israel. | Health Services |
Yeda Research & Development Co. Ltd.
Yeda Research & Development Co. Ltd. Investment ManagersFinance Yeda Research & Development Co. Ltd. engages in development of natural science and services. It covers broad of spectrum including: biotechnology, pharmaceuticals and diagnostics, bioinformatics, proteomics, biomatics and system biology, medical devices, renewable energy, bio fuels, clean technology and environmental sciences, agricultural and plants genetics, chemistry and nanotechnology, physics and electro-optics, mathematics and computer science. The company is headquartered in Rehovot, Israel. | Finance |
Enlivex Therapeutics Ltd. /Old/
Enlivex Therapeutics Ltd. /Old/ Medical SpecialtiesHealth Technology Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn’s disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company was founded by Dror Mevorach in 2005 and is headquartered in Jerusalem, Israel. | Health Technology |
ProtAb Ltd.
ProtAb Ltd. Pharmaceuticals: MajorHealth Technology ProtAb Ltd. develops drug treatment for rheumatoid arthritis. It develops therapeutic agents that modulate cytokine regulation, tipping the balance toward anti-inflammatory signaling pathways in the treatment of autoimmune inflammatory diseases. The company was Founded by Yaakov Naparstek in 2005 and is headquartered in Jerusalem, Israel. | Health Technology |
| Plantylight Ltd. | |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | Finance |
